{
  "label": "clinical_signal_03_ep_019",
  "artifact_type": "signal_episode",
  "artifact_id": "sha256:526bf0877b15ba594954d8544c6493f2535bc8acb2239824a0eeeb941d801b2d",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:161174e8025b5c956602ccc4e17b4e677c58230b1b64641f357c400c448b8151"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T11:55:21.744878",
  "content": "## 2024-07-08 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 202\n- Active: 196\n- Screen Failures Cumulative: 37\n- Withdrawals Cumulative: 6\n\n### Sites\n- Site 01 Enrolled: 20\n- Site 01 Active: 20\n- Site 01 Statin Concomitant: 6\n- Site 02 Enrolled: 15\n- Site 02 Active: 15\n- Site 02 Statin Concomitant: 3\n- Site 03 Enrolled: 18\n- Site 03 Active: 18\n- Site 03 Statin Concomitant: 5\n- Site 04 Enrolled: 13\n- Site 04 Active: 13\n- Site 04 Statin Concomitant: 3\n- Site 05 Enrolled: 17\n- Site 05 Active: 17\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 12\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 3\n- Site 07 Enrolled: 22\n- Site 07 Active: 22\n- Site 07 Statin Concomitant: 7\n- Site 08 Enrolled: 15\n- Site 08 Active: 15\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 17\n- Site 09 Active: 17\n- Site 09 Statin Concomitant: 4\n- Site 10 Enrolled: 13\n- Site 10 Active: 13\n- Site 10 Statin Concomitant: 3\n- Site 11 Enrolled: 18\n- Site 11 Active: 18\n- Site 11 Statin Concomitant: 5\n- Site 12 Enrolled: 15\n- Site 12 Active: 15\n- Site 12 Statin Concomitant: 5\n\n### Lab Panels\n- Statin Subgroup N: 54\n- Statin Subgroup ALT Mean (U/L): 103.2\n- Statin Subgroup ALT Median (U/L): 100.3\n- Statin Subgroup AST Mean (U/L): 73.7\n- Statin Subgroup AST Median (U/L): 73.6\n- Statin Subgroup Bilirubin Mean (mg/dL): 1.56\n- Statin Subgroup Bilirubin Median (mg/dL): 1.53\n- Statin Subgroup ALP Mean (U/L): 74.1\n- Statin Subgroup ALP Median (U/L): 69.1\n- Statin Subgroup Creatinine Mean (mg/dL): 0.82\n- Statin Subgroup Creatinine Median (mg/dL): 0.95\n- Statin Subgroup BUN Mean (mg/dL): 13.4\n- Statin Subgroup BUN Median (mg/dL): 13.0\n- Statin Subgroup WBC Mean (K): 7.8\n- Statin Subgroup WBC Median (K): 5.9\n- Statin Subgroup Platelets Mean (K): 262\n- Statin Subgroup Platelets Median (K): 233\n- Non-Statin Subgroup N: 120\n- Non-Statin Subgroup ALT Mean (U/L): 24.5\n- Non-Statin Subgroup ALT Median (U/L): 23.8\n- Non-Statin Subgroup AST Mean (U/L): 23.2\n- Non-Statin Subgroup AST Median (U/L): 22.3\n- Non-Statin Subgroup Bilirubin Mean (mg/dL): 0.64\n- Non-Statin Subgroup Bilirubin Median (mg/dL): 0.62\n- Non-Statin Subgroup ALP Mean (U/L): 50.8\n- Non-Statin Subgroup ALP Median (U/L): 56.3\n- Non-Statin Subgroup Creatinine Mean (mg/dL): 1.04\n- Non-Statin Subgroup Creatinine Median (mg/dL): 0.95\n- Non-Statin Subgroup BUN Mean (mg/dL): 15.2\n- Non-Statin Subgroup BUN Median (mg/dL): 12.9\n- Non-Statin Subgroup WBC Mean (K): 5.7\n- Non-Statin Subgroup WBC Median (K): 7.1\n- Non-Statin Subgroup Platelets Mean (K): 242\n- Non-Statin Subgroup Platelets Median (K): 227\n\n### Adverse Events\n- AE ID: AE-0071, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0072, Description: headache, Grade: 1, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0073, Description: fatigue, Grade: 2, Relatedness: possibly related, Resolved: true, Subject Group: statin\n- AE ID: AE-0074, Description: fatigue, Grade: 2, Relatedness: possibly related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 52\n- ACE Inhibitor Count: 28\n- Metformin Count: 21\n- PPI Count: 18\n- NSAID Count: 11\n- Other Count: 36\n\n### Protocol Deviations\n- PD ID: PD-040, Description: IP temperature excursion during shipment, 2h out of range, Severity: moderate, Site: site_08\n- PD ID: PD-041, Description: Concomitant medication not recorded at visit, Severity: minor, Site: site_07\n\n### Investigator Notes\n- Training log updated for new study coordinator\n- EDC data entry backlog cleared, queries resolved\n- Cross-site review: statin subgroup ALT out of range at Sites 01, 03, 05, 07, 09, 11; non-statin subgroup within reference range at all sites\n\n### Events\n- Drug accountability audit at Site 04: no discrepancies\n- IVRS system update deployed, randomization unaffected\n- Medical monitor weekly call completed\n\n### Notes\n- Week 19: Statin subgroup hepatic enzymes 2-3x ULN across sites. SAE reports under review. Non-statin subgroup within range.",
  "metadata": {
    "episode_id": "clinical_signal_03_ep_019",
    "scope_id": "clinical_signal_03",
    "timestamp": "2024-07-08T10:00:00",
    "phase": "escalation",
    "signal_density": "high",
    "episode_type": "signal",
    "layer_name": "signal_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "724335e48952198659b608a79f591f6985cc457d1b0726c271a193e4d218a284",
      "components": {
        "transform": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
        "inputs": "a94b84fbaca9bd62"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
      "components": {
        "transform_id": "cb4ddfa83a38701b",
        "source": "42e76241d396a578",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}